Arcus Biosciences, Inc. Revenue Breakdown
No Revenue Breakdown for RCUS on this site yet.
- 2025-12-31: Others Not split by product in the filing$33.00M100.00%; Total revenue $33.00M.
- 2024-12-31: Others Not split by product in the filing$51.00M100.00%; Total revenue $51.00M.
- 2023-12-31: Others Not split by product in the filing$37.00M100.00%; Total revenue $37.00M.
- 2022-12-31: Others Not split by product in the filing$38.00M100.00%; Total revenue $38.00M.
Source checked: the stored Revenue Breakdown page for RCUS.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $33.00M 100.00% | $33.00M |
| 2024-12-31 | Not split by product in the filing $51.00M 100.00% | $51.00M |
| 2023-12-31 | Not split by product in the filing $37.00M 100.00% | $37.00M |
| 2022-12-31 | Not split by product in the filing $38.00M 100.00% | $38.00M |
| 2021-12-31 | Not split by product in the filing $383.00M 100.00% | $383.00M |
| 2020-12-31 | Not split by product in the filing $78.00M 100.00% | $78.00M |
| 2019-12-31 | Not split by product in the filing $15.00M 100.00% | $15.00M |
| 2018-12-31 | Not split by product in the filing $8.35M 100.00% | $8.35M |
| 2017-12-31 | Not split by product in the filing $1.41M 100.00% | $1.41M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $33.00M 100.00% | $33.00M |
| 2026-03-31 | Not split by product $7.00M 100.00% | $7.00M |
| 2025-12-31 | Not split by product $11.00M 100.00% | $11.00M |
| 2025-09-30 | Not split by product $6.00M 100.00% | $6.00M |
| 2025-06-30 | Not split by product $8.00M 100.00% | $8.00M |
| 2025-03-31 | Not split by product $8.00M 100.00% | $8.00M |
| 2024-12-31 | Not split by product $23.00M 100.00% | $23.00M |
| 2024-09-30 | Not split by product $7.00M 100.00% | $7.00M |
| 2024-06-30 | Not split by product $11.00M 100.00% | $11.00M |
| 2024-03-31 | Not split by product $10.00M 100.00% | $10.00M |
| 2023-12-31 | Not split by product -$49.00M 100.00% | -$49.00M |
| 2023-09-30 | Not split by product $32.00M 100.00% | $32.00M |
| 2023-06-30 | Not split by product $29.00M 100.00% | $29.00M |
| 2023-03-31 | Not split by product $25.00M 100.00% | $25.00M |
| 2022-12-31 | Not split by product -$40.00M 100.00% | -$40.00M |
| 2022-09-30 | Not split by product $33.00M 100.00% | $33.00M |
| 2022-06-30 | Not split by product $27.00M 100.00% | $27.00M |
| 2022-03-31 | Not split by product $18.00M 100.00% | $18.00M |
| 2021-12-31 | Not split by product $354.62M 100.00% | $354.62M |
| 2021-09-30 | Not split by product $9.46M 100.00% | $9.46M |
| 2021-06-30 | Not split by product $9.46M 100.00% | $9.46M |
| 2021-03-31 | Not split by product $9.46M 100.00% | $9.46M |
| 2020-12-31 | Not split by product $9.97M 100.00% | $9.97M |
| 2020-09-30 | Not split by product $64.53M 100.00% | $64.53M |
| 2020-06-30 | Not split by product $1.75M 100.00% | $1.75M |
| 2020-03-31 | Not split by product $1.75M 100.00% | $1.75M |
| 2019-12-31 | Not split by product $9.75M 100.00% | $9.75M |
| 2019-09-30 | Not split by product $1.75M 100.00% | $1.75M |
| 2019-06-30 | Not split by product $1.75M 100.00% | $1.75M |
| 2019-03-31 | Not split by product $1.75M 100.00% | $1.75M |
| 2018-12-31 | Not split by product $1.56M 100.00% | $1.56M |
| 2018-09-30 | Not split by product $4.29M 100.00% | $4.29M |
| 2018-06-30 | Not split by product $1.25M 100.00% | $1.25M |
| 2018-03-31 | Not split by product $1.25M 100.00% | $1.25M |
| 2017-12-31 | Not split by product $1.25M 100.00% | $1.25M |
| 2017-09-30 | Not split by product $163.00K 100.00% | $163.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |